Increased Transparency Key To Combating Drug Shortages, Says US Industry Alliance
End Drug Shortages Alliance Assesses Impact Of Teva Plant Closure
The closure of a Teva manufacturing plant in California has raised concerns around access a number of medicines, something the End Drug Shortages Alliance says could be avoided through increased market transparency.
You may also be interested in...
Teva Posts $590m Negative EBITDA Amid Opioid Deal And Write-Offs
Teva’s EBITDA was in the red to the tune of more than half a billion dollars in Q2, after taking a chunk out of the company’s goodwill and adding more than $700m to its loss contingency for opioid-related claims.
Fresenius Kabi Takes On Drug Shortages With Iodixanol Launch
Fresenius Kabi has launched a generic iodixanol injection in the US, at a time when the drug is subject to a nationwide shortage. At the same time, the firm has introduced the country’s first Istodax rival.
US FDA Supply Chain Guidance Includes More Stakeholders, More Risks Than CARES Act
Draft guidance on redundancy risk management plans layers risk-based expectations over new statutory requirements to plan more resilient supply chains for critical drugs.